Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | PPARA | Q07869 | 1/20 | 0.69 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11516368 | 0.94 | LMNA (0.68) | LMNAPPARADNMT3AHDAC1HDAC6 | |
| SCHEMBL11464602 | 0.91 | PTGER4 (0.69) | LMNAPPARADNMT3AHDAC1HDAC6 | |
| SCHEMBL11356211 | 0.91 | LMNA (0.64) | LMNAPPARADNMT3AHDAC1HDAC6 | |
| SCHEMBL29617795 | 0.90 | LMNA (0.62) | LMNAPPARADNMT3AHDAC1HDAC6 | |
| SCHEMBL11706059 | 0.90 | DNMT3A (0.72) | LMNAPPARADNMT3AHDAC1HDAC6 | |
| SCHEMBL17339437 | 0.90 | LMNA (0.62) | LMNAPPARADNMT3AHDAC1HDAC6 | |
| SCHEMBL23042429 | 0.89 | PPARA (0.64) | LMNAPPARADNMT3AHPGDALDH1A1 | |
| SCHEMBL11488803 | 0.89 | PPARA (0.67) | LMNAPPARADNMT3AHDAC1HDAC6 | |
| SCHEMBL14507293 | 0.88 | LMNA (0.60) | LMNAPPARADNMT3AHDAC1HDAC6 | |
| SCHEMBL11445600 | 0.86 | LMNA (0.63) | LMNAPPARADNMT3AHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210220408-A1 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2021-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220408-A1 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE | AHR, ARNT, ARSA | LMNA 3403/4885PPARA 50/4885DNMT3A 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.